Adagene Inc
ADAG
Company Profile
Business description
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
Contact
Xinghu Street, Suzhou Industrial Park
4th Floor, Building C14, No. 218
Jiangsu Province
Suzhou215123
CHNT: +86 51287773632
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
138
Stocks News & Analysis
stocks
Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief
We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
stocks
ASX share ticks all the popular thematic boxes
The shares are overvalued as investors are overly excited about defence and gold exposure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,151.80 | 24.70 | 0.27% |
| CAC 40 | 8,350.92 | 3.72 | 0.04% |
| DAX 40 | 25,289.27 | 131.39 | -0.52% |
| Dow JONES (US) | 49,191.99 | 398.21 | -0.80% |
| FTSE 100 | 10,169.17 | 31.82 | 0.31% |
| HKSE | 26,999.81 | 391.33 | 1.47% |
| NASDAQ | 23,709.87 | 24.03 | -0.10% |
| Nikkei 225 | 54,341.23 | 2,401.34 | 4.62% |
| NZX 50 Index | 13,757.71 | 101.66 | 0.74% |
| S&P 500 | 6,963.74 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,820.60 | 29.30 | 0.33% |
| SSE Composite Index | 4,126.09 | 12.67 | -0.31% |